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ABSTRACT 
Objectives: To measure the effectiveness, safety and use of anti-Tumour necrosis Factor 
(TNF) therapy in paediatric inflammatory bowel disease (PIBD) in the United Kingdom 
(UK). 
Methods: Prospective UK audit of patients newly starting anti-TNF therapy. Disease 
severity was assessed using Physician Global Assessment (PGA) +/or the Paediatric 
Crohn’s Disease Activity Index (PCDAI). 
Results: 37 centres participated (23 of 25 specialist PIBD sites). 524 patients were 
included; 429 Crohn’s disease (CD), 76 ulcerative colitis (UC), 19 IBD unclassified 
(IBDU). 87% (488/562) anti-TNF was infliximab; commonest indication was active 
luminal CD 77% (330/429) or chronic refractory UC/IBDU 56% (53/95); 79% (445/562) 
had concomitant co-immunosuppression. In CD (267/429 male), median time from 
diagnosis to treatment was 1.42 years (IQR 0.63-2.97). Disease (at initiation) was 
moderate or severe in 91% (156/171) by PGA compared to 41% (88/217) by PCDAI; 
Kappa (Κ) 0.28 = only ‘fair agreement’ (p<0.001).  
Where documented, 77% (53/69) of CD patients responded to induction; and 65% 
(46/71) entered remission. 2287 infusions and 301.96 years of patient follow-up (n=385) 
are represented; adverse events affected 3% (49/1587) infliximab and 2% (2/98) 
adalimumab infusions (no deaths or malignancies). Perianal abscess drainage was less 
common after anti-TNF initiation (CD): 26% (27/102) before, 7% (3/42) after (p=0.01); 
however pre and post anti-TNF data collection was not over equal time periods. 
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Conclusion: Anti-TNFs are effective treatments, usually given with thiopurine co-
immunosuppression. This study highlights deficiencies in formal documentation of effect 
and disparity between disease severity scoring tools which need to be addressed to 
improve ongoing patient care. 
 
Keywords: Paediatric gastroenterology, inflammatory bowel disease, Crohn’s disease, 
ulcerative colitis, biologics (IBD) 
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What is known: 
 Anti-Tumour necrosis Factor (TNF) therapy is a very effective treatment for 
refractory paediatric Inflammatory bowel disease. 
 There are concerns about use of co-immunosuppression and potential increased 
lymphoma risk. 
 Physician Global Assessment (PGA) and Paediatric Crohn’s disease activity index 
(PCDAI) are frequently used measures of disease activity 
What is new: 
 Formal documentation of response/ remission rates to induction anti-TNF therapy 
is infrequent. 
 The majority of patients in this large cohort are on combination therapy, usually 
with thiopurines. 
 There was disparity between PGA and PCDAI scores; weighted PCDAI is 
suggested as an alternative. 
 
 
 
 
 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
INTRODUCTION 
The Inflammatory Bowel Diseases (IBD), comprising Crohn’s disease (CD), ulcerative 
colitis (UC) and IBD unclassified (IBDU) are increasing in incidence and prevalence, 
notably in the paediatric population.1 Paediatric care has been revolutionised in the last 
decade by the widespread introduction of anti-tumour necrosis factor (anti-TNF) therapy, 
both infliximab (IFX) and adalimumab (ADA); registration clinical trials have shown 
these agents to be effective where other therapies have failed.2,3 Paediatric onset IBD 
(PIBD) tends to be more extensive at diagnosis and aggressive in behaviour4,5 and use of 
anti-TNF therapy is proportionately greater in the paediatric population compared to 
adults (20% in adolescents vs 8% in adults in one case control study)6.  
IFX and ADA have been licensed for use in PIBD in the UK since 2010 and 2013 
respectively; UK survey data has demonstrated effectiveness in treating refractory disease 
whilst highlighting the potential for serious side effects.7,8 Scottish data on 132 PIBD 
patients treated with biologics over a decade show response rates of 87% with IFX (48% 
remission) and 76% with ADA (35% remission) replicating safety issues, especially 
serious infection.9  
The UK IBD audit is a national gastrointestinal audit first commenced in 2006 (reporting 
in 2008). Reports are available online at www.rcplondon.ac.uk/ibd. Data has previously 
been published on the outcomes of paediatric and adult patients with UC.10,11 We aimed 
to collect data on anti-TNF therapies in UK PIBD practice to assess effectiveness, safety 
and appropriate use (according to national guidelines) in clinical practice. Unselected, 
large scale national data will help quantify and categorise adverse events where real life 
clinical data is lacking. 
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MATERIALS AND METHODS 
Sites (either a single hospital or a represented health board or trust) were eligible to 
participate in the audit if they prescribe and administer anti-TNF therapies to their 
patients with IBD, on a voluntary basis. A total of 37 sites participated, including 23 of 
25 specialist PIBD sites, representing a broad subset of PIBD patients across the UK. 
Children with a diagnosis of IBD who were aged 18 years or younger when newly started 
on anti-TNF therapy for IBD from 12/09/11 were eligible for inclusion. Patients already 
on anti-TNF therapy prior to this date were excluded. Data was collected prospectively 
and entered into a bespoke web based database, with security maintained through local 
site codes and the lead clinician for the site authorising local access. All treatment 
decisions and data entry were at the discretion of the treating physician. Data capture for 
the results included here ended on 28/02/14.  
Demographic details were pseudo-anonymised at the point of data entry and identifiable 
only to the participating site. IBD disease details were phenotyped according to Montreal 
criteria for disease location and behaviour.12 Physician Global Assessment (PGA), 
Paediatric Crohn’s Disease Activity Index (PCDAI) or Paediatric Ulcerative Colitis 
Activity Index (PUCAI) scores were collected at initial and follow-up treatments, along 
with details of comorbidities and any surgery.13,14,15 A full list of all data items collected 
is available on request. 
Acute infusion reactions were as decided by the treating clinical team responsible for the 
patient; no specific guidance on specific timing was given to teams. Each follow-up 
treatment relates to an initial submission and records outcome as intention to continue or 
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stop; response with or without remission using reduction in PCDAI/PUCAI or Harvey 
Bradshaw Index (HBI).16 Unlimited numbers of follow-up treatments are permitted and 
any adverse events recorded. Poor response was used to describe those patients with no 
or limited response to anti-TNF treatment, which included primary non-responders. 
Details of IBD related surgery can be added at any time, along with any escalation of 
treatment at each initial or follow-up treatment. Patient Reported Outcome Measures 
(PROM) data was collected using the IMPACT-III questionnaire 17–19 at initiation and 
subsequently.  
Some children received treatment with multiple biologics resulting in more initial 
treatments than patients. Since the number of submissions per patient is variable (e.g. 
multiple initial or follow-up treatments), the denominators presented vary considerably; 
results tables should therefore be scrutinised carefully in conjunction with any 
explanatory notes for accurate interpretation.  
Guidance on the use of anti-TNF therapy in the UK comes via the National Institute for 
Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC). 
NICE Technology Appraisals TA187 (CD) and TA329 (UC) recommend Infliximab [and 
adalimumab] within its licensed indication as an option for “the treatment of people aged 
6-17 years with severe active disease who have not adequately responded to conventional 
therapy (including corticosteroids, immunomodulators and exclusive enteral nutrition 
[CD]), or who cannot tolerate or have contraindications to conventional therapy”.7,20 Data 
were collected on disease type and severity as well as previous therapies to assess 
prescribing against these criteria. 
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Selected data, including demographics, disease location and response to treatment were 
compared to data reported in the adult arm of the audit from the same time period, which 
can be seen at www.rcplondon.ac.uk/ibd.21 
Data were analysed using SPSS version 19 (IBM Corp. Released 2010. IBM SPSS 
Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.). Data manipulation was 
performed using SAS software v9.4 for Windows. Copyright (c) 2002-2012 by SAS 
Institute Inc., Cary, NC, USA. SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.  
Chi-squared test and the kappa statistic were used to examine categorical data; the Mann-
Whitney U test was used to examine continuous data; Kolmogorov-Smirnov (KS) test 
was used to analyse PROM data. Kappa statistic is expressed as per the boundaries 
described by Landis and Koch; range is from ‘poor/slight’ agreement (Κ ≤0.2) through 
‘fair’, ‘moderate’ and ‘substantial’, to ‘almost perfect’ agreement (Κ 0.81-1.00). A p 
value of <0.05 was considered statistically significant. 
 
ETHICAL CONSIDERATIONS 
As an audit of clinical practice, ethical permission was not applied for. 
 
RESULTS 
Overview 
By 28/02/14, demographic submissions were entered on 817 individual paediatric 
patients; 156 patients with no initial treatment details entered were excluded leaving 661 
patients with 746 initial treatments (some patients were treated with more than one anti-
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TNF). Further exclusions resulted in final analysis on 524 patients (429 CD, 76 UC and 
19 IBDU) with 562 initial treatments (Figure 1). Patient demographics are shown in table 
1. 30 CD, 4 UC and 4 IBDU patients were treated with both anti-TNFs. 
Infliximab was the commonest anti-TNF therapy representing 87% (488/562) of initial 
treatments. 79% (445/562) patients were co-immunosuppressed; 79% (386/488) on IFX 
(91% thiopurines [351/386], 9% methotrexate [35/386]) and 80% (59/74) on ADA (80% 
thiopurines [47/59], 20% methotrexate [12/59]). Consent was taken in 99% (559/562), 
either verbally (46% [257/559]) or written (54% [302/559]). Verbal consent was 
significantly more common with ADA 51/74 (69%) compared with IFX 206/485 (42%), 
p=0.00002. In total 51% (223/437) of patients had failed on an immunosuppressant 
and/or steroids prior to treatment with anti-TNF. 5.2% patients (27/524) had no previous 
medication or concomitant therapies documented at time of anti-TNF initiation, 
suggesting a ‘top-down’ therapy approach. 
Crohn’s Disease 
40% (151/379) of patients starting IFX and 37% (22/60) starting ADA had extensive 
disease i.e. L3 (ileocolonic) at initiation and 80% (310/388) had upper GI involvement 
(proximal = L4). The commonest indication for starting therapy was active luminal CD in 
78% (355/458); severe perianal CD accounted for 17% (77/458) (Supplemental Digital 
Content, Table 1, http://links.lww.com/MPG/B43).  
Disease severity at initiation of anti-TNF (where documented) was moderate-severe in 
91% (156/171, PGA) and 41% (88/217, PCDAI) (table 2). 
Cross-tabulation of PCDAI and PGA (grouping mild and remission together for 
comparison) reveals a Kappa statistic (Κ) of 0.28 (SE=0.055, p<0.001) indicating only 
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‘fair agreement’. PCDAI was less frequently recorded than PUCAI; 51% (217/429) 
PCDAI compared to 64% (53/76) PUCAI, p=0.02.  
99% (347/349) of initial IFX was given at 5mg/kg i.e. standard dosing. 71% (45/63) 
ADA was given at 80mg/40mg whilst 25% (16/63) was given at 160mg/80mg induction 
dose. Outcomes of treatment are shown in table 3; of note, planned withdrawal following 
effective treatment occurred in just 21% (9/42) of IFX cessation and no cases with ADA.  
Ulcerative Colitis 
The majority of patients had extensive disease (E3) at initiation (table 1). Chronic 
refractory UC was the commonest indication (59% [47/79] treatments) but 39% (31/79) 
were for acute severe UC (Supplemental Digital Content, Table 1, 
http://links.lww.com/MPG/B43). All IFX infusions were prescribed at 5mg/kg and 86% 
(6/7) of ADA given at 80mg/40mg induction dose. 
Disease severity was moderate-severe in 92% (35/38, PGA) compared to 85% (45/53, 
PUCAI). Median PUCAI score at initiation was 55 (IQR 40, 70), (table 2). Cross-
tabulation had a Kappa statistic of 0.58 indicating ‘moderate’ agreement (0.41-0.60) 
between PGA and PUCAI.22 
There was 97% follow-up for ongoing IFX treatments (168/174), median 94 days (IQR 
21, 215) and 83% (5/6) for ongoing ADA treatments, median 130 days (IQR 114, 304). 
12% treatments were stopped (21/173), with poor response or loss of response equally 
accounting for 76% (16/21). Where PGA was documented, disease severity (n=100) 
improved in most at follow-up (n=38) (table 2). 
IBD Unclassified 
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95% (20/21) of IBDU patients had extensive disease (E3) at initiation. Acute severe and 
chronic refractory IBDU accounted for an equal proportion of treatments. There was 97% 
follow-up for ongoing anti-TNF at a median of 44 days (IQR 14, 98) for IFX. 16% 
treatments were stopped (n=5); poor response (2/5), adverse effects (2/5), loss of 
response (1/5). Disease severity where recorded at follow-up was mild in 10%, moderate 
in 76% and severe in 14% (n=21), compared to 0% mild, 22% moderate and 78% severe 
at initiation (n=9). 
Disease severity was moderate-severe in 100% (9/9) IBDU at initiation by PGA, where 
documented, compared with 62% (5/8) by PUCAI.  
Response and remission 
Response to induction was infrequently formally recorded; 17% (89/524) all IBD (CD 
74/429, UC 12/76, IBDU 3/19). 75% (67/89) patients responded (fall in PCDAI ≥15, fall 
in PUCAI ≥20 or remission) at 10-14 week follow-up (CD 78% [58/74], UC/IBDU 60% 
[9/15]); 60% (56/93) achieved remission (CD 64% [50/78], PCDAI score ≤10 and 
UC/IBDU 40% [6/15], PUCAI <10). 
Surgery 
105 paediatric patients had surgery involving 156 IBD-related surgical procedures. There 
was no significant difference between surgery in the 6 months pre and post initiating 
biologic; 7% (36/524) pre and 5% (27/524) post (p= 0.30). 87% (136/156) procedures 
were in CD patients, 8% (13/156) in UC patients and 5% (7/156) in patients with IBDU. 
The commonest surgical procedure in UC/ IBDU was sub-total colectomy with 
ileostomy. The commonest procedures (by disease type) are detailed in Supplemental 
Digital Content, Table 2, http://links.lww.com/MPG/B44. The commonest procedure 
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overall was examination under anaesthetic (EUA) of fistula, 24% (40/166) of all surgical 
procedures, 27% (39/144) CD procedures. Drainage of perianal abscess was significantly 
less common in CD after anti-TNF than before 28% (27/96) vs. 8% (3/39) (p=0.01). 
However the time period of data collection was not equal pre and post anti-TNF and was 
variable from patient to patient. In total, 16% (12/74) of UC patients went on to have 
colectomy (Supplemental Digital Content, Table 2, http://links.lww.com/MPG/B44). 
Safety data 
There were 2287 infusions and 301.96 years of patient follow-up (n=385); median 0.65 
(IQR 0.27-1.19). 
2% (10/488) of all initial IFX infusions and 1% of all follow-up IFX infusions (23/1587) 
reported an acute reaction. There were no acute reactions with any ADA treatment 
(0/173). 3% (49/1587) of IFX and 2% (2/98) ADA infusions reported an adverse event, 
most commonly infection (Supplemental Digital Content, Table 3, 
http://links.lww.com/MPG/B45), although type and severity of infection was not 
specified. 10% of CD patients (32/316) experienced at least one adverse event over the 
course of their treatment. No malignancies or mortality were reported. 
Pre-treatment Screening 
Tuberculosis (TB) screening was carried out: 97% (478/493) had at least 1 test for TB ; 
88% (433/492) patients had a chest x-ray, 47% (224/481) a gamma interferon TB test and 
3% (15/469) a Mantoux test. 71% (343/485) patients were screened for Varicella 
immunity; 46% (221/482) for Hepatitis B infection and 37% (176/480) for Hepatitis C; 
12% (57/476) were screened for HIV infection.  
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Comparison to adult data 
Comparison was made to data from the adult biologic audit which ran over the same time 
period. There was a male preponderance in the paediatric cohort, with more extensive 
disease distribution and shorter time from diagnosis to anti-TNF initiation. 
Response and remission rates were comparable but more children were co-
immunosuppressed at the time of starting anti-TNF (Supplemental Digital Content, Table 
4, http://links.lww.com/MPG/B46). 
Patient Reported Outcome Measures (PROM) 
19% (98/524) had IMPACT-III scores recorded at baseline with 33% (32/98) with a 
repeat at follow-up (Supplemental Digital Content, Table 5, 
http://links.lww.com/MPG/B47). The median (IQR) baseline score for IBD was 110.5 
(91.0, 129.0) and at follow-up 113.5 (82.0, 141.0) and for CD (n=78) 110.5 (92.0, 130.0) 
and 128.5 (85.0, 147.5) respectively. When considering patients with both baseline and 
follow-up scores (CD n=25, all IBD n=32) CD; 98.0 (87.0, 136.0) to 109.0 (72.0, 156.0), 
and ‘all IBD’; 103.5 (87.0, 131.5) to 101.0 (68.0, 147.5) (ns for both). It should be noted 
that a change of 10.8 or more is considered a significant change by the IMPACT-III 
design team.23 
 
DISCUSSION 
This large cohort of paediatric patients receiving anti-TNF therapy over a 2.46 year 
period gives a snapshot of use in real life clinical practice for PIBD across the UK.  
Overall response and remission rates are good (75% patients responding and 60% 
achieving remission), but one of the key outcomes is that formal documentation of this is 
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infrequently done (17% patients). This is despite patients going on to receive 
maintenance therapy after their induction course. We highlight the need for formal post-
induction assessment of response to determine the need for on-going treatment and 
suggest a validated scoring system as the best method. Failure to do this formally is 
highly concerning; patients may continue to receive treatment that is failing or not have 
appropriate investigations performed e.g. trough level determination.  
Complete accrual of all anti-TNF use, effectiveness and safety has been published in a 
nationwide Scottish PIBD registry study, but this only represents 8% of the UK paediatric 
population.9 Lower remission rates of 48% and 36% for IFX and ADA respectively were 
reported here but the period studied was longer 2000 – 2010, perhaps reflecting early use 
of anti-TNF when current standard practice, such as maintenance rather than episodic 
treatment and dose optimisation, was not in place.9 A previous UK survey of adalimumab 
for paediatric CD reported a remission rate of 61% at follow-up8 and the RESEAT study 
a 65-71% clinical response rate at 3-12 months of ADA therapy in paediatric CD,24 
which are comparable despite our low documentation rate. 
There is a clear discrepancy between PGA and PCDAI scores. Documentation of PCDAI 
at follow-up was low, as in previous studies, thought potentially due in part to the 
inclusion of items that are less readily obtained such as height velocity, perianal 
examination and laboratory indices.15,25 Formal documentation of such data can be seen 
as a low priority in busy clinical practice. PCDAI was less frequently recorded than 
PUCAI here, which may support the theory that a simpler score is better used. Recently, 
the weighted PCDAI (wPCDAI)  has been proposed as an alternative measure to the 
PCDAI and shown to have validity despite the exclusion of haematocrit, abdominal 
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examination and height velocity as parameters.26 Replacing PCDAI with wPCDAI in 
subsequent rounds of the audit may encourage increased completion and thereby 
facilitate more objective clinical assessment and aid decision making.  An app to allow 
easy calculation of wPCDAI and documentation was produced as a result of this study. 
The PUCAI appeared to have better correlation with PGA than PCDAI, in keeping with 
other studies specifically designed to test this which show excellent agreement.15  
There was a significant reduction in the need for drainage of perianal abscess after 
initiation with anti-TNF. We note that time periods pre and post initiation were not equal 
or defined, limiting the strength of any conclusions drawn from this, but we know that 
perianal disease is recognised as a debilitating CD phenotype and anti-TNFs have been 
shown to be an effective treatment in large studies.27 The rate of colectomy in UC 
patients at 16% is in keeping with adult studies28,29, rate of colectomy post anti-TNF in 
IBDU patients is notable at 21% but numbers are small (4/19). 
Although the follow-up period is relatively short (max 2.46 years), the large number of 
patients allows us some confidence in the short term safety profile of the anti-TNF 
therapies, as 2287 infusions and 302 years of patient follow-up are represented. Infection 
was the commonest adverse event, in keeping with other published studies30,9 and whilst 
risks are minimised where possible, total prevention is not achievable. Despite safety 
concerns about the use of combination therapy and lymphoma risk, it is interesting to 
note that the majority of patients in this cohort were on combination therapy. Recently 
published registry data from a very large cohort of paediatric patients (some from the 
UK) have shown no increased risk of malignancy during longer term follow up, 
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supporting the good safety profile of infliximab,31 as with previous anti-TNF safety 
data.32 
Screening practice is variable; exclusion of TB infection is an obligatory part of 
guidelines so there remains room for improvement in the final unscreened 3%.33,34  The 
risk of hepatitis B reactivation is well known but despite this less than half of patients 
were screened, highlighting a need to improve on this.  
The shortened time from diagnosis to starting anti-TNF in the paediatric population 
compared to adults is striking; it suggests aggressive progression of disease and rapid 
cycling though medical therapeutic options, although potentially reflects poorer tolerance 
of standard treatments and the context of aiming for steroid free remission as quickly as 
possible to minimise impact on growth, puberty and education. 
It is difficult to draw any meaningful conclusion regarding impact on quality of life 
(QoL) due to the small numbers of documented PROMs. Completion in subsequent audit 
rounds should be promoted as improvement in QoL is an important outcome and cannot 
be assumed from other markers of response. Of note, significant improvement in QoL 
using IMPACT 3 in paediatric patients has been recently documented in a formal clinical 
study.35 
The main limitation of this study is the variability in completeness of data capture, 
reflected in the changing denominator for different categories of data. This audit relies on 
clinical centres finding time to enter patient data and it is often only possible for them to 
supply the minimum data set. By comparison it is a major undertaking to capture all 
biological usage and outcomes in a PIBD population.9 Follow-up is relatively short 
therefore the ongoing medical and surgical course of those who do not respond is 
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unknown. Its strength however lies in the nationwide collaborative nature of the project 
and relatively large numbers represented, with over 90% of specialist sites participating 
and the ‘real-world’ clinical data which should mean conclusions that can be drawn are 
broadly generalisable to the PIBD population. Addressing the major issue of poor 
documentation of post induction response is likely to result in a significant improvement 
in the clinical care PIBD patients. The large number of treatments in routine clinical use 
support anti-TNF therapy as safe and effective in paediatric IBD with the majority of 
patients achieving response or remission and just 2% of initial infusions and 1% of 
follow-up infusions associated with acute adverse reactions.  
Future audit is increasingly important with bio-similars now licensed for use in PIBD in 
the UK; generating comparative clinical data on their efficacy and safety profile is 
essential to evaluate their use, given the current lack of any published evidence in IBD. 
Ongoing national collaboration would be the best way to achieve this quickly and 
meaningfully.    
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Fig 1. Patient flow chart. CD, Crohn’s Disease; UC, Ulcerative Colitis; IBDU 
Inflammatory Bowel Disease Unclassified.  
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Summary table CD 
n=429 
UC 
n=76 
IBDU 
n=19 
All IBD 
n=524 
General patient characteristics 
Gender: Male 62% (267/429) 58% (44/76) 53% (10/19) 61% (321/524) 
Age at diagnosis, 
years, median 
(IQR) 
n=411 
12.0 (9.4, 13.8) 
n=74 
12.3 (9.5, 14.2) 
n=17 
11.7 (8.9, 12.8) 
n=502 
12.0 (9.4, 13.9) 
Age at initial 
treatment, years, 
median (IQR) 
n=427 
14.2 (13.5, 15.7) 
n=76 
13.1 (11.7, 15.4) 
n=19 
13.5 (11.0, 14.8) 
n=522 
14.1 (12.3, 15.7) 
Time from 
diagnosis to 
biologic, years, 
median (IQR) 
n=411 
1.43 (0.65, 3) 
n=74 
1.08 (0.3, 2.23) 
n=17 
0.82 (0.06, 3.5) 
n=502 
1.36 (0.61, 2.92) 
Commonest disease distribution at decision to initiate treatment (by Montreal classification) 
Colonic (L2) 40% (164/410) ‐ ‐  
Ileocolonic (L3) 41% (166/410) ‐ ‐  
Any gut proximal 
to TI (L4) 
79% (288/364) ‐ ‐  
Perianal 
involvement = Yes 
54% (146/270) ‐ ‐  
Extensive colitis 
(E3) 
‐ 74% (54/73) 94% (16/17) 78% (70/90) 
 
 
Table 1: Overview of demographics and disease details by IBD type. IQR, Inter Quartile Range; PCDAI, 
Paediatric Crohn’s Disease Activity Index; PUCAI, Paediatric Ulcerative Colitis Activity Index 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Disease severity 
at initial 
treatment (per 
patient)  
CD 
n=429 
UC 
n=76 
IBDU 
n=19 
All IBD 
n=524 
PGA 
Mild 
Moderate 
Severe 
n=171 
9% (15/171) 
55% (94/171) 
36% (62/171) 
n=38 
8% (3/38) 
45% (17/38) 
47% (18/38) 
n=9 
0% (0/9) 
22% (2/9) 
78% (7/9) 
n=218 
8% (18/218) 
52% (113/218) 
40% (87/218) 
PCDAI 
median (IQR) 
≤10 (Remission) 
11‐30 (Mild) 
31‐37.5(Moderate)   
>40 (Severe) 
n=217 
29 (20, 38) 
12% (26/217) 
47% (103/217) 
17% (36/217) 
24% (52/217) 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
‐ 
n=217 
29 (20, 38) 
‐ 
‐ 
‐ 
 
PUCAI 
median (IQR) 
0‐9 (Remission) 
10‐34 (Mild) 
35‐64 (Moderate) 
65‐85 (Severe) 
‐ 
‐ 
‐ 
‐ 
‐ 
n=53 
55 (40, 70) 
4% (2/53) 
11% (6/53) 
42% (22/53) 
43% (23/53) 
n=8 
43 (15, 58) 
25% (2/8) 
13% (1/8) 
38% (3/8) 
25% (2/8) 
n=61 
55 (39, 66) 
7% (4/61) 
11% (7/61) 
41% (25/61) 
41% (25/61) 
 
 
 
 
 
 
 
 
Table 2: Disease severity at initial treatment. PGA, Physician Global Assessment; IQR, Inter Quartile Range; 
PCDAI, Paediatric Crohn’s Disease Activity Index; PUCAI, Paediatric Ulcerative Colitis Activity Index.
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Crohn’s Disease 
Follow‐up anti‐TNFα 
treatment 
Infliximab 
(Frequency %) 
n=1414 
Adalimumab 
(Frequency %) 
n=97 
Follow‐up outcome 
Seen for follow‐up 98% (1389/1414) 91% (88/97) 
Transitioned to adult care 2% (23/1414) 8% (8/97) 
Transferred to another service 0.1% (2/1414) 1% (1/97) 
Median days from initial dose to 
follow‐up (IQR) 
167 (46, 350) 81 (35, 232) 
Current plan 
Continue treatment 97% (1346/1388) 91% (84/92) 
Stop treatment 3% (42/1388) 9% (8/92) 
Reason for stopping (if treatment stopped)
Treatment effective and 
discontinued 
21% (9/42) 0% (0/8)
Loss of response 17% (7/42) 38% (3/8) 
Poor response 29% (12/42) 50% (4/8) 
Side effects / adverse events 14% (6/42) 0% (0/8)
Other 19% (8/42) 13% (1/8) 
Disease severity (PGA) 
Mild 69% (500/726) 26% (17/65) 
Moderate 26% (186/726) 51% (33/65) 
Severe 6% (40/726) 23% (15/65) 
Table 3: Outcome at follow‐up in Crohn’s Disease; IQR, Inter Quartile Range; PGA, Physician Global 
Assessment 
Table 3: Outcome at follow‐up in Crohn’s Disease; IQR, Inter Quartile Range; PGA, Physician Global 
Assessment 
